Dexlansoprazole Capsule, Delayed Release
Product Images NDC 72162-2239

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Dexlansoprazole (NDC 72162-2239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Dexlansoprazole 01)

Chemical structure of dexlansoprazole, the active ingredient in Dexlansoprazole delayed release 60 mg capsules. The diagram shows the molecular arrangement including heterocyclic rings and the trifluoromethyl group.*

FDA Label Image

Figure 1 (Dexlansoprazole 02)

A line graph illustrating plasma concentration (ng/mL) over time (hours) for dexlansoprazole 30 mg and 60 mg doses. It shows how plasma concentration changes from 0 to 24 hours post-administration, with the 60 mg dose consistently achieving higher plasma concentrations compared to the 30 mg dose.*

FDA Label Image

Label (Lbl721622239)

Label for Dexlansoprazole delayed-release capsules, 60 mg strength, containing 30 capsules. The label includes storage instructions, dispensing warnings, and a barcode. It is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by TWi Pharmaceuticals, Inc. The NDC number 72162-2239-3 is visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.